CSL (OTCMKTS:CSLLY) Shares Gap Down – Should You Sell?
by Mitch Edgeman · The Markets DailyCSL Limited Sponsored ADR (OTCMKTS:CSLLY – Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $60.97, but opened at $57.22. CSL shares last traded at $59.7090, with a volume of 14,831 shares changing hands.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on CSLLY. Canaccord Genuity Group raised shares of CSL from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. Zacks Research cut shares of CSL from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 18th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy”.
CSL Price Performance
The company has a current ratio of 2.46, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. The business’s 50-day simple moving average is $62.43 and its two-hundred day simple moving average is $71.98.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Further Reading
- Five stocks we like better than CSL
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Why Amazon Could Be a $300 Stock Within Weeks
- The Role Economic Reports Play in a Successful Investment Strategy
- Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside
- Manufacturing Stocks Investing
- MarketBeat Week in Review – 12/8 – 12/12